Recruiting Ankylosing Spondylitis Studies in London
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and saf...
An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894)....
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with g...
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to...
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9...
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
Study J3Z-MC-OJAE is a Phase 1/2, multicenter, open-label, dose-finding study of LY3884961 evaluating the safety and tolerability in adults with peripheral manifestations of GD. Up to 3 dose levels o...
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized my...
About Ankylosing Spondylitis Clinical Trials in London
Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.
There are currently 7 ankylosing spondylitis clinical trials recruiting participants in London, ONTARIO. These studies are seeking a combined 541 participants. Research is being sponsored by Sanofi, Crinetics Pharmaceuticals Inc., Walden Biosciences and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ankylosing Spondylitis Clinical Trials in London — FAQ
Are there ankylosing spondylitis clinical trials in London?
Yes, there are 7 ankylosing spondylitis clinical trials currently recruiting in London, ONTARIO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in London?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the London research site will contact you about next steps.
Are clinical trials in London free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many London studies also compensate for your time and travel.
What ankylosing spondylitis treatments are being tested?
The 7 active trials in London are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.
Data updated March 2, 2026 from ClinicalTrials.gov